

IV 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表・平成21年度

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ito I, Kawasaki A, Ito S, Kondo S, Sugihara M, Horikoshi M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Takasaki Y, Hashimoto H, Matsuta K, Sumida T, and Tsuchiya N.	Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population.	Ann. Rheum. Dis.			in press
Segawa S, Goto D, Yoshiga Y, Sugihara M, Hayashi T, Chino Y, Matsumoto I, Ito S, Ito S, and Sumida T.	Inhibition of TGF- β signaling attenuates IL-18 plus IL-2-induced interstitial lung disease.	Clin. Exp. Immunol.			in press
Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, Tsutsumi A, Uchida K, Usui J, Yamagata K, and Sumida T.	Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis.	Clin. Exp. Immunol.	159	1-10	2010
Iwanami K, Matsumoto I, Tanaka Y, Inoue A, Minami R, Hayashi T, Goto D, Ito S, Nishimura Y, and Sumida T.	Altered peptide ligands inhibit glucose-6-phosphate isomerase (GPI) peptide-induced arthritis.	Arthritis Res. Ther.	11	R167	Epub2009 Nov9
Inoue A, Matsumoto I, Tanaka Y, Iwanami K, Goto D, Ito S, and Sumida T.	Tumor necrosis factor- α -induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis.	Arthritis Res. Ther.	11	R118	Epub2009 Aug6
Tanaka-Watanabe Y, Matsumoto I, Iwanami K, Inoue A, Goto D, Ito S, Tsutsumi A, and Sumida T.	B cells play crucial role as antigen-presenting cells and collaborate with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritis.	Clin. Exp. Immunol.	155	285-294	2009
Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham R.R., Takasaki Y, Hashimoto H, Ohashi J, Behrens T.W., Sumida T, and Tsuchiya N.	Replication of the association between C8orf13-BLK region and systemic lupus erythematosus in a Japanese population.	Arthritis Rheum.	60	553-558	2009
Kawaguchi Y, Wakamatsu E, Matsumoto I, Nishimagi E, Kamatani N, Satoh T, Kuwana M, Sumida T, and Hara M.	Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.	Ann. Rheum. Dis.	68	710-714	2009
Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, Hayashi T, Goto D, Matsumoto I, and Sumida T.	A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.	Mod. Rheumatol.	19	358-365	2009
Wakamatsu E, Matsumoto I, Yoshiga Y, Iwanami K, Tsuboi H, Hayashi T, Goto D, Ito S, and Sumida T.	Altered peptide ligands regulate type II collagen-induced arthritis in mice.	Mod. Rheumatol.	19	366-371	2009
Segawa S, Goto D, Yoshiga Y, Hayashi T, Matsumoto I, Ito S, and Sumida T.	Low levels of soluble CD1d protein alters NKT cell function in patients with rheumatoid arthritis.	Int. J. Mol. Med.	24	481-486	2009

Horikoshi M, Ito S, Ishikawa M, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Goto D, Matsumoto I, and Sumida T.	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab.	Mod. Rheumatol.	19	229-234	2009
Shimohata H, Yamada A, Yoh K, Ishizaki K, Morito N, Yamagata K, Takahashi S.	Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background.	J. Nephrol.	22	123-129	2009
Maeda A, Moriguchi T, Hamada M, Kusakabe M, Fujioka Y, Nakano T, Yoh K, Lim K.C., Engel J.D., Takahashi S.	Transcription factor GATA-3 is essential for lens development.	Dev. Dyn.	238	2280-2291	2009
Honda, S.I., Kurita, N., Miyamoto, A., Cho, Y., Usui, K., Takeshita, K., Takahashi, S., Yasui, T., Kikutani, H., Kinoshita, T., Fujita, T., Tahara-Hanaoka, S., Shibuya, K., Shibuya, A.	Enhanced humoral immune responses against T-independent antigens in Fc(alpha)/(micro)R-deficient mice.	Proc. Natl. Acad. Sci. USA.	106	11230-11235	2009
Arimura Y, Ezaki T, Koyanagi M, Uchiyama T, Koyasu S. and Yagi, J.	Reduced T cell expansion by a superantigen due to impaired B cell development in mice deficient for the p85a regulatory subunit of PI3K.	J. Leuc. Biol.			in press
Nitta T, Murata S, Sasaki K, Fujii H, Ripen A. M., Ishimaru N, Koyasu S, Tanaka K. and Takahama, Y.	Thymoproteasome shapes immunocompetent repertoire of CD8 T cells.	Immunity	32	29-40	2010
Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J.-I., Ohtani M, Fujii H. and Koyasu, S.	Innate production of Th2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells.	Nature	463	540-544	2010
Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, Dranoff, G. and Tahara, H.	Milk fat globule EGF-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms.	J. Exp. Med.	206	1317-1326	2009
Gilio K, Munnix, I. C., Mangin P, Cosemans J. M., Feijge, M. A., van der Meijden, P. E., Olieslagers S, Chrzanowska-Wodnicka M. B, Lillian R., Schoenwaelder S, Koyasu S, Sage S O, Jackson S P, Heemskerk J W.	Non-redundant roles of phosphoinositide 3-kinase isoforms a and b in glycoprotein VI-induced platelet signaling and thrombus formation.	J. Biol. Chem.	284	33750-33762	2009
Nagamatsu K, Kuwae K, Konaka T, Nagai S, Watanabe M, Yoshida S, Mimuro H, Koyasu S, and Abe A.	Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN.	J. Exp. Med.	206	3073-3088	2009
Ito I, Kawasaki A, Ito S, Kondo Y, Sugihara M, Horikoshi M, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Takasaki Y, Hashimoto H, Matsuta K, Sumida T, Tsuchiya N.	Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population.	Ann Rheum Dis.			in press
Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T.	A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment.	Intern. Med	49	187-189	2010

Wang Y, Ito S, Chino Y, Goto D, <u>Matsumoto I</u> , Murata H, Tsutsumi A, Hayashi T, Uchida K, Usui J, Yamagata K, Sumida T.	Laser Microdissection-based Analysis of Cytokine Balance in the Kidneys of Patients with Lupus Nephritis.	Clin. Exp. Immunol.	159	1-10	2010
Iwanami K, <u>Matsumoto I</u> , Yoshiga Y, Inoue A, Kondo Y, Yamamoto K, Tanaka Y, Minami R, Hayashi T, Goto D, Ito S, Nishimura Y, Sumida T.	Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide.	Arthritis Res Ther.	11	R167	2009
Inoue A, <u>Matsumoto I</u> , Tanaka Y, Iwanami K, Kanamori A, Ochiai N, Goto D, Ito S, Sumida T.	Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis.	Arthritis Res Ther.	11	R118	2009
Segawa S, Goto D, Yoshiga Y, Hayashi T, <u>Matsumoto I</u> , Ito S, Sumida T.	Low levels of soluble CD1d protein alters NKT cell function in patients with rheumatoid arthritis.	Int. J. Mol. Med.	24	481-486	2009
Kawaguchi Y, Nakamura Y, <u>Matsumoto I</u> , Nishimagi E, Kamatani N, Satoh T, Kuwana M, Sumida T, Hara M.	Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility	Ann Rheum Dis.	68	710-714	2009
Tsutsumi A, Kobayashi T, Ito S, Goto D, <u>Matsumoto I</u> , Yoshie H, Sumida T.	Mannose binding lectin gene polymorphisms and the severity of chronic periodontitis.	Jap. J. Clin. Immunol	32	48-52	2009
Horikoshi M, Ito S, Ishikawa M, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Goto D, <u>Matsumoto I</u> , Sumida T.	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show reduced or insufficient response to infliximab.	Mod Rheumatol	19	229-234	2009
Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, Hayashi T, Goto D, <u>Matsumoto I</u> , Sumida T.	A new low-field extremity magnetic resonance imaging and proposed compact MRI score- Evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.	Mod Rheumatol	19	358-365	2009
Kondo Y, Ito S, Ohi Y, Satou H, Hiraoka T, Tsuboi H, Sugihara M, Hayashi T, Goto D, <u>Matsumoto I</u> , Sumida T.	A case of atypical Cogan's Syndrome with aortitis.	Intern. Med	48	1093-1097	2009
Wakamatsu E, <u>Matsumoto I</u> , Yoshiga Y, Hayashi T, Goto D, Ito S, Sumida T.	Altered peptide ligands regulate type II collagen-induced arthritis in mice.	Mod Rheumatol	19	366-371	2009
Tanaka-Watanabe Y, <u>Matsumoto I</u> , Iwanami K, Inoue A, Goto D, Ito S, Tsutsumi A, Sumida T.	B cell play crucial role as antigen presenting cells and collaborations with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritis.	Clin Exp Immunol.	155	285-294	2009
Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, <u>Matsumoto I</u> , Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N.	Replication of the Association between C8orf13-BLK Region and Systemic Lupus Erythematosus in a Japanese Population.	Arthritis Rheum.	60	553-558	2009
松本功	免疫グロブリン・補体・免疫複合体	リウマチ・膠原病内科 クリニカルスタンダード2009			in press

松本功	関節炎における自己抗体の病因的意義	最新医学			in press
松本功	生物学的製剤の開始を考慮するときの留意事項	日本内科学会雑誌	98	2518-2523	2009
松本功	新規関節リウマチ治療薬開発における動物モデルの有用性	リウマチ科	42	574-581	2009
松本功	抗GPI抗体は関節リウマチの病態に関与しているか？	分子リウマチ治療	2	105-109	2009
松本功、岩波慶一	GPI誘導性関節炎におけるIL-6/IL-17の役割	Frontiers in Rheumatology & Clinical Immunology	3	82-86	2009
井上明日香、松本功、岩波慶一、田中陽子、住田孝之	TNF α 依存性関節炎モデル(GPI誘導性関節炎)におけるTNF α -induced adipose related protein (TIARP)	日本臨床免疫学会雑誌	32	15-19	2009
松本功、岩波慶一	自己免疫性関節炎におけるIL-6/IL-17の役割	リウマチ科	41	96-103	2009
Nonomura Y, Mizoguchi F, Suzuki A, Nanki T, Kato H, Miyasaka N, Kohsaka H.	Hypoxia-induced Abrogation of Contact-dependent Inhibition of Rheumatoid Arthritis Synovial Fibroblast Proliferation	J Rheumatol	36	698-705	2009
Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H.	Intervention of an Inflammation Amplifier, Triggering Receptor Expressed on Myeloid Cells 1, for Treatment of Autoimmune Arthritis	Arthritis Rheum	60	1615-1623	2009
Bohgaki M, Matsumoto M, Atsumi T, Kondo T, Yasuda S, Horita T, Nakayama KI, Okumura F, Hatakeyama S, Koike T.	Plasma gelsolin facilitates interaction between beta(2) glycoprotein I and alpha5beta1 integrin.	J Cell Mol Med			in press
Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yasuda S, Koike T.	Complement activation in patients with primary antiphospholipid syndrome.	Ann Rheum Dis	68	1030-1035	2009
Horita T, Atsumi T, Yoshida N, Nakagawa H, Kataoka H, Yasuda S, Koike T.	STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome.	Ann Rheum Dis	68	1366-1367	2009
Nakagawa H, Yasuda S, Matsuura E, Kobayashi K, Ieko M, Kataoka H, Horita T, Atsumi T, Koike T.	Nicked β 2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property.	Blood	114	2553-2559	2009
akai Y, Atsumi T, Ieko M, Amengual O, Furukawa S, Furusaki A, Bohgaki M, Kataoka H, Horita T, Yasuda S, Koike T.	The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation.	Arthritis Rheum	60	2457-2467	2009
Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, Ohta K, Yasuda S, Koike T, Minakami H.	Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes	J Reprod Immunol	79	188-195	2009

Bohgaki T, Atsumi T, Bohgaki M, Furusaki A, Kondo M, Sato-Matsumura KC, Abe R, Kataoka H, Horita T, Yasuda S, Amasaki Y, Nishio M, Sawada K, Shimizu H, Koike T.	Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.	J Rheumatol.	36	1240-8	2009
Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, Kohriyama T, Sobue G, Yamamura T, Itoyama Y, Saida T, Sakata K, Ochi H, Matsuoka T.	Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years.	Mult. Scler.	15	159-173	2009
Ishizu T, Kira J.I, Osoegawa M, Fukazawa T, Kikuchi S, Fujihara K, Matsui M, Kohriyama T, Sobue G, Yamamura T, Itoyama Y, Saida T, Sakata K.	Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey.	J.Neurol. Sci.	280	22-28	2009
Satoh J.I, Tabunoki H, Yamamura T	Molecular network of the comprehensive multiple sclerosis brain-lesion proteome.	Mult. Scler.	15	531-41	2009
Klemann C, Raveney B.J.E, Klemann A.K, Ozawa T, von Hörsten S, Shudo K, Oki S, Yamamura T	Synthetic retinoid AM80 inhibits Th17 cells and ameliorates EAE.	Am. J. Pathol.	174	2234-45	2009
Theil M.M, Miyake S, Mizuno M, Tomi C, Croxford J.L, Hosoda H, Theil J, von Hoersten S, Yokote H, Chiba A, Lin Y, Oki S, Akamizu T, Kangawa K, Yamamura T	Suppression of experimental autoimmune encephalomyelitis by Ghrelin.	J. Immunol.	183	2859-66	2009
Fujita M, Otsuka T, Mizuno M, Tomi C, Yamamura T, Miyake S.	Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via an iNKT cell-dependent mechanism.	Am. J. Pathol.	175	1116-23	2009
Klemann C, Raveney B.J.E, Oki S, Yamamura T	Retinoid signals and Th17-mediated pathology.	Jpn. J. Clin. Immunol.	32	20-28	2009
Croxford J.L, Yamamura T	Back to the future for multiple sclerosis therapy: Focus on current and emerging disease-modifying therapeutic strategies.	Immunotherapy	1	403-23	2009
Miyake S, Yamamura T	Ghrelin: friend of Foe for Neuroinflammation.	Discov. Med.	8	64-7	2009
山村 隆	多発性硬化症の分子標的医薬開発の現状.	BRAIN and NERVE	61	923-8	2009
山村 隆, 千葉健治	自己免疫疾患の治療薬開発-病態の多様性を見据えて.	Yakugaku Zasshi	129	647-8	2009
大木伸司, 山村 隆	多発性硬化症の病態形成とオーファン核内受容体NR4A2.	臨床免疫・アレルギー科	52	111-8	2009
宮崎雄生, 山村 隆	NKT細胞と自己免疫.	医学のあゆみ (最新・自己免疫疾患Update-研究と治療の最前線)	3230	651-6	2009

大木伸司, 山村 隆	多発性硬化症の病態解析から治療標的の同定へ.	Jpn. J. Clin. Immunol.	32	214-22	2009
山村 隆, 横手裕明, 三宅幸子	腸内細菌と自己免疫.	Current Insights in Neurological Science	17	10-1	2009
山村 隆	多発性硬化症. 連載 サイトカインと炎症性疾患・自己免疫疾患-その病態における役割と治療展開-.	炎症と免疫	18	87-91	2010
Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, Yamamoto K.	CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2.	Proc Natl Acad Sci U S A.	106	13974-9	2009
Ishikawa S.	Children's immunology, what can we learn from animal studies (3): Impaired mucosal immunity in the gut by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD): A possible role for allergic sensitization.	J. Toxicol. Sci.	34	SP349-361	2009
Abe J, Ueha S, Suzuki J, Tokano Y, Matsushima K, and Ishikawa S.	Increased Foxp3+CD4+ regulatory T cells with intact suppressing activity but altered cellular localization in murine lupus.	Am. J. Pathol.	173	1682-1692	2008
Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y.	A calcineurin inhibitor, tacrolimus overcomes treatment-unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.	J Rheumatol			in press
Tsujimura S, Saito K, Nakayamada S, Tanaka Y.	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis.	Mod Rheumatol			in press
Ikenouchi-Sugita A, Yoshimura R, Kishi T, Umene-Nakano W, Katsuki A, Saito K, Iwata H, Tanaka Y, Nakamura J.	No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients.	World J Biol Psychiatry			in press
Sawamukai N, Yukawa s, Saito K, Nakayamada S, Kambayashi T, Tanaka Y.	Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling.	Arthritis Rheum			in press
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T.	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study.	Ann Rheum Dis			in press
Choo Q-Y, Ho PC, Tanaka Y, Lin H-S.	Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.	Rheumatology			in press

Suzuki K, Nakawaga H, Kameda H, Amano K, Kondo T, Itoyama S, <u>Tanaka Y</u> , Takeuchi T.	Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus.	Rheumatology	48	198-199	2009
Komano Y, Harigai H, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, <u>Tanaka Y</u> , Takeuchi T, Miyasaka N.	Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.	Arthritis Care Research	61	305-312	2009
Matsuura A, Tsukada J, Mizobe T, Higashi T, Mouri F, Tanikawa R, Yamauchi A, Hirashima M, <u>Tanaka Y</u> .	Intracellular galectin-9 activates inflammatory cytokines in monocytes.	Genes Cells	14	511-521	2009
Koike T, Harigai M, Inokuma S, Inoue, Ishiguro N, Ryu J, Takeuchi T, <u>Tanaka Y</u> , Yamanaka H, Fujii K, Freundlich B, Suzukawa M.	Post-marketing surveillance of the safety and effectiveness of etanercept in Japan	J Rheumatol	36	898-906	2009
Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Hanami K, <u>Tanaka Y</u> .	Effects of anti-TNF- α antibody infliximab in refractory entero-Behçet's disease.	Rheumatology	48	1012-1013	2009
Nakano K, Higashi T, Takagi R, Hashimoto K, <u>Tanaka Y</u> , Matsushita S.	Dopamine released by dendritic cells polarizes Th2 differentiation.	Int Immunol	21	645-654	2009
Tanikawa T, Okada Y, Tanikawa R, <u>Tanaka Y</u> .	Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.	J Vascular Res	46	572-580	2009
Nakayama S, Fujimoto T, Nonomura A, Saito K, Nakamura S, <u>Tanaka Y</u> .	Usefulness of initial histological features for stratifying Sjogren's syndrome	Rheumatology	48	1279-1282	2009
Hirose A, Tanikawa T, Mori H, Okada Y, <u>Tanaka Y</u> .	Advanced glycation end products increase endothelial permeability through RAGE/Rho signaling pathway.	FEBS Lett	584	61-66	2009

研究成果の刊行に関する一覧表（平成21年度）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
		書籍名	出版地	ページ
Sakuishi, K., Miyake, S., Yamamura, T.	NK cells and NKT cells in MS.	Gramm, U.	Springer-Verlag	2009
		The Immune System Series "Results and Problems in Cell Differentiation"	Heidelberg	in press
荒浪利昌, 山村 隆	多発性硬化症.	松島綱治, 西脇 徹	朝倉書店	2009
		炎症・再生医学事典	東京	216-8
岡本智子, 山村 隆	脱髄性疾患. 急性散在性脳脊髄炎.	鈴木規宏	総合医学社	2009
		神経疾患・診療ガイドライン-最新の診療指針-	東京	195-7
荒浪利昌, 山村 隆	EAE/experimental allergic encephalomyelitis.	桂 義元, 山本一彦, 小安重夫, 河本 宏	朝倉書店	2009
		免疫の辞典	東京	216-8
田中 良哉	関節リウマチ	山口昭生	岩波書店	2009
		40歳からの女性の医学 関節リウマチ 新しい治療、正しい知識で克服する	東京	1-123
田中 良哉	全身エリテマトーデス	山口徹, 北原光夫, 福井次矢	医学書院	2009
		今日の治療方針 2009年版 —私はこう治療している	東京	608-610
田中 良哉	生物学的製剤 ～抗サイトカイン療法を中心に～	松島綱次, 西脇徹	朝倉書店	2009
		炎症・再生医学辞典	東京	344-347
田中 良哉	膠原病・リウマチ性疾患の薬物治療免疫抑制薬、抗リウマチ薬、生物学的製剤	小川聰	中山書店	2009
		内科学書	東京	151-154

v 平成21年度班会議プログラム

プログラム

13 : 00～13 : 05 開会の辞

13 : 05～13 : 15 厚生労働省 挨拶

13 : 15～ 研究発表

1. 13 : 15～13 : 35

T細胞分化誘導分子の強発現による自己免疫疾患制御法の開発に関する研究
筑波大学大学院人間総合科学研究科疾患制御医学専攻臨床免疫学
住田 孝之

2. 13 : 35～13 : 55

免疫疾患における TH1/TH2 細胞の役割と制御に関する研究
筑波大学大学院人間総合科学研究科生命システム医学専攻分子発生生物学
高橋 智

3. 13 : 55～14 : 15

Collagen induced arthritis (CIA)における樹状細胞の役割と機能の解析
慶應義塾大学医学部
小安 重夫

4. 14 : 15～14 : 35

新規 TNF α 誘導性蛋白 TIARP/STEAP4 の自己免疫性関節炎における役割に関する研究
筑波大学大学院人間総合科学研究科疾患制御医学専攻臨床免疫学
松本 功

5. 14 : 35～14 : 55

E3 ユビキチンリガーゼ c-MIR の抗炎症効果による関節炎治療に関する研究
東京医科歯科大学大学院医歯学総合研究科膠原病・リウマチ内科学
上阪 等

… … … コーヒーブレイク 14:55～15:10 … … …

6. 15:10～15:30

自己免疫疾患における免疫担当細胞のシグナル異常とその制御
(関節リウマチにおける RasGRP4 の発現検討)

北海道大学大学院医学研究科 内科学講座・第二内科
小池 隆夫

7. 15:30～15:50

多発性硬化症における Mucosal Associated Invariant T 細胞に関する研究

国立精神・神経センター神経研究所免疫研究部
山村 隆

8. 15:50～16:10

新規 IL-10 産生制御性 T 細胞の分化機構に関する研究

東京大学医学部アレルギー・リウマチ内科
藤尾 圭志

9. 16:10～16:30

自己免疫疾患におけるケモカイン・ケモカインレセプターの役割と制御戦略に関する研究：SLE モデルにおける濾胞性ヘルパー T 細胞の増加と B1 細胞による T_{FH} 様細胞誘導

東京大学大学院医学系研究科
石川 昌

10. 16:30～16:50

SLE における自己抗体産生機構と B 細胞を分子標的とした治療戦略に関する研究

産業医科大学医学部第一内科学講座
田中良哉

16:50～16:55 閉会の辞

VI 研究成果刊行物・別刷

Inhibition of transforming growth factor- β signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice

S. Segawa, D. Goto, Y. Yoshiga,
M. Sugihara, T. Hayashi, Y. Chino,
I. Matsumoto, S. Ito and T. Sumida
Division of Clinical Immunology, Doctoral
Program in Clinical Sciences, Graduate School of
Comprehensive Human Sciences, University of
Tsukuba, Tsukuba, Ibaraki, Japan

Accepted for publication 15 December 2009
Correspondence: Takayuki Sumida, Division of
Clinical Immunology, Doctoral Program in
Clinical Sciences, Graduate School of
Comprehensive Human Sciences, University of
Tsukuba, 1-1-1, Tennoudai, Tsukuba, Ibaraki,
305-8575, Japan.
E-mail: tsumida@md.tsukuba.ac.jp

Summary

Interstitial lung disease (ILD) is an intractable disease induced by various factors in humans. However, there is no universally effective treatment for ILD. In this study, we investigated the role of transforming growth factor (TGF)- β signalling in the pathogenesis of ILD by using model mice. Injection of interleukin (IL)-18 plus IL-2 in C57BL6 (B6) mice resulted in acute ILD by infiltration of natural killer (NK) cells and a significant increase of TGF- β mRNA in the lung. To examine the pathogenetic role of TGF- β in ILD mice, we used SB-431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide), which is a potent and selective inhibitor of TGF- β receptor I (T β RI), also known as activin receptor-like kinase 5 (ALK5). Treatment of B6-ILD mice with SB-431542 resulted in improvement of ILD, delay in mortality, reduction of the expression of interferon (IFN)- γ and IL-6 in the lungs. The same treatment also decreased significantly the percentage of natural killer (NK) cells in the lungs ($P < 0.05$) and mRNA expression levels of certain chemokines such as CCL2, CCL3, CCL4, CCL5 and CXCL10 in B6-ILD. These findings were confirmed by IL-18 plus IL-2 treatment of Smad3-deficient (Smad3^{-/-}) mice ($P < 0.05$). Our results showed that inhibition of TGF- β signalling reduced the percentage of NK cells and the expression of certain chemokines in the lungs, resulting in improvement of ILD. The findings suggest that TGF- β signalling may play an important role in the pathogenesis of IL-18 plus IL-2-induced ILD in mice.

Keywords: activin receptor-like kinase 5, chemokines, interstitial lung disease, pathogenesis, SB-431542, TGF- β signalling

Introduction

Interstitial lung disease (ILD) is an intractable disease induced by various factors such as autoimmune diseases, drugs, occupational and environmental exposure [1]. However, there is no universally effective treatment for ILD. On the other hand, chemotherapy with bleomycin (BLM) and busulphan is reported to cause lung fibrosis in some patients [2]. Histopathologically, diffuse infiltration of mononuclear and polymorphonuclear leucocytes is observed in the lung in the early stages of human ILD. Following the interstitial inflammation, florid fibroblast proliferation within both the interstitium and alveolar space is often detected. The same pathology is observed in BLM-induced ILD in mice [1]. Previous studies suggested that various mediators, such as cytokines and chemokines, including tumour necrosis factor (TNF)- α , transforming

growth factor (TGF)- β , interleukin (IL)-1 β , macrophage inflammatory factor (MIP)-1 α /CCL3, monocyte chemoattractant protein (MCP)-1/CCL2, reactive oxygen species (ROS) and Fas/Fas ligand interactions, are associated with BLM-induced ILD and fibrosis in mice [3–9].

IL-18, a member of the IL-1 family, is a proinflammatory cytokine [10,11] known to induce interferon (IFN)- γ production synergistically by stimulation with IL-12, IL-2, antigens and IFN- α . Previous studies reported that IL-18 can potentially induce Th2 cytokines from T cells, natural killer (NK) cells, NK T cells, basophils and mast cells [11–16]. Thus, IL-18 can act as co-factor for both T helper type 1 (Th1) and Th2 cell development. In BLM-induced ILD mice models, there were two conflicting reports on the effect of IL-18. Nakatani-Okuda *et al.* [17] reported that IL-18 played a protective role in BLM-induced ILD in mice. In contrast, Hoshino *et al.* [18] reported that IL-18 played a






Fig. 1. Expression of transforming growth factor (TGF)-β mRNA after injection of interleukin (IL)-18 plus IL-2. Expression of TGF-β mRNA was analysed by real-time-polymerase chain reaction (RT-PCR). C57BL/6 (B6) mice were injected intraperitoneally with a single dose of IL-18/IL-2. At 3, 6, 12 and 24 h after injection, mice were killed and lung mRNA was extracted. Data are mean ± standard error of the mean; *n* = 3 mice per group. **P* < 0.05; one-way analysis of variance.

pathogenetic role in the ILD. Therefore, the intimate role of IL-18 in ILD was controversial. Recently, Okamoto *et al.* [19] reported a new mouse model of ILD induced by IL-18 plus IL-2 (IL-18/IL-2). Daily administration of IL-18 with IL-2, but not IL-18 or IL-2 alone, produced a synergistic effect and induced ILD in mice. Unlike BLM-induced ILD, lung fibrosis was not caused in IL-18/IL-2-induced ILD. The pathological condition of BLM-induced ILD was mainly fibroblastic proliferation [20]. However, little fibroblastic proliferation was found in IL-18/IL-2-induced ILD. This model of ILD is characterized by severe infiltration of NK cells, mononuclear cells and polymorphonuclear leucocytes in the lung. Furthermore, the mortality in this two ILD mice models was different. Whereas 60% of mice died at 30 days after BLM treatment [21], 100% of mice died at 7 days after IL-18/IL-2 injection. Based on rapid and severe cell infiltration in IL-18/IL-2-induced ILD, the mouse model is considered suitable for early-phase human ILD.

Various chemokines, such as CCL2, CCL3, CCL4, CCL5, CXCL1 and CXCL8, are induced by activated fibroblasts in

Fig. 2. Effects of SB-431542 in interleukin (IL)-18 plus IL-2-induced interstitial lung disease (ILD) mice. (a) B6 mice were injected with IL-18/IL-2 with or without SB-431542 for 10 days, as described in Materials and methods. ○, phosphate = interstitial lung disease (ILD) –buffered saline (PBS) + vehicle; ●, PBS + SB-431542; □, IL-18/IL-2 + vehicle; ■, IL-18/IL-2 + SB-431542; *n* = 5 mice per group. Data are representative of three independent experiments and graph shows pooled data of three experiments. **P* < 0.05; Kaplan–Meier method. (b) Lungs were harvested from B6 mice at 24 h after injected with IL-18/IL-2 with or without SB-431542 for 3 days. Lung tissues were stained with haematoxylin and eosin. Original magnification: ×100. (c) Lungs were harvested from B6 mice at 6 h after injection with IL-18/IL-2 with or without SB-431542 for 3 days. (d) The sera were harvested from B6 mice at 6 h after injection with IL-18/IL-2 with or without SB-431542 for 3 days. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). ELISA assayed the lung tissue supernatant as described in Materials and methods. Data are mean ± standard error of the mean; *n* = 3 mice per group. **P* < 0.05; Student’s *t*-test.



the lung tissue [22]. Mice with BLM-induced pulmonary fibrosis exhibit up-regulation of CCL2, CCL5, CCL3 and CXCL1 in the lung and such overexpression is associated with enhanced fibroblast proliferation and collagen production [23]. Thus, these chemokines are thought to be involved in the pathogenesis of ILD and subsequent fibrotic process. In contrast, the functional roles of chemokines in IL-18/IL-2-induced ILD in mice remain elusive, although lymphotactin (Ltn), CCL2, CCL3, CCL4, CCL5, CCL11, CXCL1 and CXCL10 are increased in the lung [19].

TGF- β is thought to be one of the pathogenic factors in ILD. Previous reports suggested that TGF- β acts as a regulatory molecule with pleiotropic effects on cell proliferation, differentiation, migration and survival [24]. TGF- β mediates its biological functions via binding to TGF- β receptor II (T β RII) and phosphorylation of TGF- β receptor I (T β RI), also known as activin receptor-like kinase 5 (ALK5). After forming the TGF- β -T β RII-ALK5 complex, ALK5 phosphorylates intracellular signal mediators Smad2/3. The importance of ALK5-mediated Smad2/3 activation in TGF- β signalling has been confirmed both *in vitro* and *in vivo* [24–29].

SB-431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide) is a potent and selective inhibitor of ALK-5 [30–32]. Inhibition of ALK-5 suppressed BLM-induced pulmonary fibrosis [33]. However, the therapeutic potential of ALK-5 inhibitor in IL-18/IL-2-induced ILD has not yet been clarified.

In the present study, we examined the role of TGF- β signalling in early-stage ILD. For this purpose, we used

SB-431542 and Smad3-deficient (*Smad3*^{-/-}) mice for IL-18/IL-2-induced ILD. The results demonstrated that inhibition of TGF- β signalling suppressed accumulation of NK cells and reduced mRNA expression of CCL2, CCL3, CCL4, CCL5 and CXCL10 in the lung. The main message of this study is that Smad-mediated TGF- β signalling seems to play an important role in the pathogenesis of IL-18/IL-2-induced ILD.

Materials and methods

Mice

C57BL/6 (B6) mice were purchased from Charles River Japan Inc. (Tokyo, Japan). Smad3-deficient (*Smad3*^{-/-}) mice were kindly provided by Dr Chuxia Deng (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA) [34]. The genotypes of both B6 and *Smad3*^{-/-} mice were determined by polymerase chain reaction (PCR) analysis on tail DNA obtained from 4-week-old animals. Female mice were used in this study. The animals were kept under specific pathogen-free conditions and studied at 4–5 weeks of age. The Institutional Animal Care and Use Committee at Tsukuba University approved the experimental protocol.

Cell isolation and purification

Pulmonary lymphocytes were isolated as described previously [35], with the following modifications. The lung was




Fig. 2. Continued

perfused thoroughly with phosphate-buffered saline (PBS) to remove circulating blood cells. The dissected lung was minced in PBS containing 1 mM ethylenediamine tetraacetic acid (EDTA). The minced lung tissue was suspended in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum (FBS) (BioWest, FL, USA), 1 mM EDTA and 1 mM dithiothreitol (DTT). The suspension was incubated at 37°C for 45 min with gentle shaking. The resultant suspension was passed through nylon mesh to remove debris. The washed and recovered cells were subjected to Lympholyte (Cedarlane, Ontario, Canada) at 1100 g at room temperature for 20 min. The resultant interface containing pulmonary lymphocytes was recovered and washed with RPMI-1640 medium containing 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 50 µM 2-mercaptoethanol. Spleens were harvested and haemolyzed with PBS. Single-cell suspensions were prepared in RPMI-1640 medium containing 10% FBS, 100 units/ml of penicillin, 100 µg/ml streptomycin and 50 µM 2-mercaptoethanol.

Antibodies and flow cytometry

All antibodies were used according to the recommendations of the respective manufacturers. For flow cytometric analysis, cells were preincubated with anti-CD16/32 (eBioscience, San Diego, CA, USA) to block Fc receptors. The following antibodies were used in this study: phycoerythrin (PE)-conjugated anti-natural killer (NK)1.1 (PK136) (Biolegend, San Diego, CA, USA) and PE/cyanine 7 (Cy7)-conjugated anti-CD3ε (145-2C11) (Biolegend). The stained cells were analysed on CyAn advanced digital processing (ADP) (Dako, Glostrup, Denmark) and data were processed using Summit4.3 (Dako).

Induction of lung fibrosis with IL-18 and IL-2

Recombinant human IL-2 (rhIL-2) and recombinant mouse IL-18 (rmIL-18) were obtained from MBL (Nagoya, Japan). Mice were treated once a day with an intraperitoneal (i.p.) injection of rhIL-2 (100 000 U) and/or rmIL-18 (1 µg). These cytokines were suspended in sterile 200 µl PBS. Mice treated with 200 µl PBS served as the control group. Following treatment for 3 days, mice were bled and killed. Pulmonary lymphocytes and splenocytes were analysed by flow cytometry.

Treatment of mice with SB-431542

ALK-5 inhibitor, SB-431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide) (SB-431542) was obtained from Tocris Bioscience (Park Ellisville, MO, USA). It was suspended in sterile dimethyl sulphoxide (DMSO) at 20 mg/ml. Mice were treated twice a day (0 h and

12 h after IL-18/IL-2 treated) by i.p. injection of 50 µl (0.2 mg) SB-431542 or vehicle for 3 days.

Reverse transcription polymerase chain reaction (RT-PCR) analysis

Total RNA was extracted from the lung, and was reverse transcribed into cDNA using RevertAid™ first-strand cDNA synthesis kit (Fermentas, Burlington, Ontario, Canada), according to the manufacturer's protocol. For amplification of chemokine cDNA, after an initial denaturation step at 94°C for 4 min, 35 cycles were conducted each at 94°C for 30 s followed by 60°C for 30 s and 72°C for 30 s, and further extension at 72°C for 7 min. For amplification of glyceraldehyde-2-phosphate dehydrogenase (GAPDH) cDNA, PCR assays were performed for 30 cycles (94°C for 30 s followed by 60°C for 30 s and 72°C for 30 s). At the end of cycles, samples were stored at 4°C until analysed. After amplification, the PCR products were separated by electrophoresis in 2.0% agarose gels. The primer sequences were as follows and the PCR product sizes [base pairs (bp)] were indicated: CCL2, 5'-AGGTCCCTGTCATGCTTCTG, 3'-TC TGGACCCATTCTTCTTG (249 bp); CCL3, 5'-AGATTC CACGCCAATTCATC, 3'-CTCAAGCCCCTGCTCTACAC (223 bp); CCL4, 5'-CCCACTTCCCTGCTGTTTCTC, 3'-GA GGAGGCCTCTCCCTGAAGT (238 bp); CCL5, 5'-CCCTC ACCATCATCCTCACT, 3'-CCTTCGAGTGACAAACACGA (185 bp); CCL11, 5'-TCCACAGCGTCTTATTCT, 3'-CTA TGGCTTTCAGGGTGCAT (178 bp); CXCL1, 5'-GCTGGG ATTACCTCAAGAA, 3'-TCTCCGTTACTTGGGGACAC (180 bp); CXCL10, 5'-GGATGGCTGTCCTAGCTCTG, 3'-ATAACCCCTTGGGAAGATGG (211 bp); and GAPDH, 5'-CGTCCCGTAGACAAAATGGGT, 3'-GAATTTGCCGT GAGTGGAGT (177 bp).

Quantification of gene expression by RT-PCR

The cDNA samples were amplified with specific primers and fluorescence-labelled probes for the target genes. Specific primers and probes for TGF-β and GAPDH were purchased from Applied Biosystems Japan (Tokyo, Japan). The amplified product genes were monitored on an ABI 7700 sequence detector (Applied Biosystems Japan). The quantitative PCR master mix was purchased from Applied Biosystems Japan. The final concentrations of the primers were 200 nM for each of the 5' and 3' primers, and the final probe concentration was 100 nM. The thermal cycler conditions used were 50°C for 2 min, 95°C for 10 min, then 50 cycles of 95°C for 15 s and 60°C for 1 min. Serial dilutions of a standard sample were included in every assay, and standard curves for the genes of interest and GAPDH genes were generated. All measurements were performed in triplicate. The level of gene expression was calculated from the standard curve, and expressed relative to GAPDH gene expression.




Fig. 3. Immunohistochemical findings of phosphorylated Smad3 (p-Smad3) in lungs of B6 mice treated with SB-431542. (a) Lungs were harvested from B6 mice at 6 h after treatment with interleukin (IL)-18/IL-2 with or without SB-431542 for 3 days. The tissues were stained immunohistochemically with anti-pSmad3 antibody. Arrow: pSmad3-positive cells. Original magnification: $\times 200$. (b) In lungs of mice treated with IL-18/IL-2 with or without SB-431542, the percentage of p-Smad3-positive cells per total cells was calculated in five fields under $\times 200$ magnification. Data are mean \pm standard error of the mean of three mice per group. * $P < 0.05$; Student's *t*-test.

Histological examination

For histological analysis, mice were euthanized by isopropanol and lung was fixed with 4% paraformaldehyde. Lung tissues were stained with haematoxylin and eosin (H&E).

Immunohistochemistry

In the present study, anti-phosphorylated Smad3 were used (Rockland, Gilbertsville, PA, USA). For detection of immunocomplexes, Histofine (Nichirei Corporation, Tokyo, Japan) for phosphorylated Smad3 was used using the manufacturer's instructions. Substitution of the primary antibody with irrelevant immunoglobulin G (IgG) served as negative controls. Staining was repeated for each sample at least three times. After counterstaining with haematoxylin, sections

were mounted with mounting agent, PARAmount-D (Falma, Tokyo, Japan).

Measurement of cytokines in the lung and serum

For enzyme-linked immunosorbent assay (ELISA), the lung tissue was suspended and homogenized in sterile PBS and centrifuged at 10 000 *g* for 10 min. The cytokine levels in the lung tissue supernatants and the serum were evaluated by ELISA (R&D Systems, Minneapolis, MN, USA).

Statistical analysis

Data are expressed as median or mean \pm standard error of the mean (s.e.m.). Data were analysed using a statistical software package (StatView 5.0; SAS Institute Inc, Cary, NC, USA). The survival rates were analysed by Kaplan–Meier method. Differences between groups were examined for statistical significance using Student's *t*-test. For multiple group comparisons, one-way analysis of variance (ANOVA) was performed followed by a *post-hoc* Dunnett's test. A *P*-value less than 0.05 denoted a statistically significant difference.

Results

Overexpression of TGF- β mRNA in IL-18/IL-2-induced ILD

Figure 1 shows significant up-regulation of TGF- β mRNA in the whole lung tissues from mice at 3, 6 and 12 h after injection of IL-18/IL-2 compared with 0 h ($P < 0.05$, $P < 0.01$ and $P < 0.05$, respectively). However, at 24 h after injection of IL-18/IL-2, the expression of TGF- β mRNA returned to the level at 0 h.

SB-431542 ameliorated ILD and reduced the expression of IFN- γ and IL-6 in the lung

Treatment with SB-431542 was employed to examine the effect of TGF- β inhibition on IL-18/IL-2-induced ILD. As shown in Fig. 2a, treatment with SB-431542 delayed mortality significantly compared with control on the 11th day ($P < 0.05$). Histological examination showed inhibition of cell infiltration in the lungs of SB-431542-treated ILD mice compared with the control (Fig. 2b). Furthermore, we analysed the expression of cytokines in sera and the lung tissues from SB-431542 and vehicle-treated ILD-induced mice. In the lung of SB-431542-treated mice, the expression of IFN- γ and IL-6 was significantly lower than control mice ($P < 0.05$, $P < 0.01$, Fig. 2c). However, in sera, the expression of IFN- γ and TNF- α was not different in each group (Fig. 2d). The lung wet–dry ratio was not significantly different between SB-431542-treated ILD mice and vehicle-treated ILD mice (data not shown).




Fig. 4. Flow cytometric analysis of pulmonary lymphocytes in B6 mice treated with SB-431542. (a) Pulmonary lymphocytes were harvested from B6 mice at 24 h after treatment with interleukin (IL)-18/IL-2 with or without SB-431542 for 3 days, as described in Materials and methods. Pulmonary lymphocytes were stained with phycoerythrin (PE)-conjugated anti-natural killer (NK)1.1 and PE/cyanine 7 (Cy7)-conjugated anti-CD3 ϵ monoclonal antibodies. (b) Left: proportion of NK cells relative to pulmonary lymphocytes in mice treated with IL-18/IL-2 and with or without SB-431542. Right: proportion of NK cells relative to splenocytes in B6 mice treated with IL-18/IL-2 with or without SB-431542. Data are mean \pm standard error of the mean of three mice per group. * $P < 0.05$; Student's *t*-test.

SB-431542 ameliorates lowers percentage of phosphorylated Smad3-positive cells

Furthermore, the number of phosphorylated Smad3-positive cells was lower in the lung of B6 mice treated with SB-431542 compared with the control (Fig. 3a). To confirm this result, we counted the percentage of p-Smad3-positive cells relative to the total number of cells. The percentage of p-Smad3-positive cells was significantly lower in SB-431542-treated ILD mice ($24.98 \pm 6.11\%$) compared with the control ($41.12 \pm 4.92\%$, $P < 0.05$, Fig. 3b).

SB-431542 significantly reduces NK cells in the lung

The results showed significantly fewer NK cells ($22.53 \pm 5.90\%$) in the lungs of SB-431542-treated B6 mice compared with the control ($34.84 \pm 4.43\%$, $P < 0.05$, Fig. 4a and b). In contrast, the percentage of NK cells in splenocytes of SB-431542-treated B6 mice ($11.50 \pm 2.13\%$) tended to be higher than the control ($8.99 \pm 0.82\%$, Fig. 4b).

Improvement of ILD and reduced cell infiltration in lungs of Smad3^{-/-} mice

We also conducted experiment in Smad3^{-/-} mice for further assessment of the role of TGF- β signalling on IL-18/IL-2-induced ILD [31]. Histological examination showed milder cell infiltration in the lungs of Smad3^{-/-} mice compared with the control (Fig. 5a). Furthermore, flow cytometry showed a significantly small proportion of NK cells in the lung of Smad3^{-/-} mice treated with IL-18/IL-2 ($22.77 \pm 3.27\%$) compared with B6 mice ($33.89 \pm 5.06\%$, $P < 0.05$, Fig. 5b and c).

Underexpression of chemokine mRNAs in lung of SB-431542-treated and Smad3^{-/-} mice

RT-PCR showed that the expression levels of CCL2, CCL3, CCL4, CCL5 and CXCL10 mRNAs were lower in the lungs of B6 mice treated with SB-431542 than the control (Fig. 6a). Furthermore, the expression levels of CCL2, CCL3, CCL4, CCL5, CCL11, CXCL1 and CXCL10 were lower in the lungs of Smad3^{-/-} mice than the control (Fig. 6b).




Fig. 5. Histological and flow cytometric analysis of pulmonary lymphocytes in Smad3^{-/-} mice. (a) Lungs were harvested from B6 and Smad3^{-/-} mice at 24 h after treated with interleukin (IL)-18/IL-2 for 3 days. Lung tissues were stained with haematoxylin and eosin. Original magnification: $\times 100$. (b) Pulmonary lymphocytes were harvested from B6 and Smad3^{-/-} mice at 24 h after treatment with IL-18/IL-2 for 3 days, as described in Materials and methods. Pulmonary lymphocytes were stained with phycoerythrin (PE)-conjugated anti-natural killer (NK)1.1 and PE/cyanine 7 (Cy7)-conjugated anti-CD3 ϵ monoclonal antibodies. (c) Proportion of NK cells relative to pulmonary lymphocytes in B6 and Smad3^{-/-} mice treated with IL-18/IL-2. Data are mean \pm standard error of the mean of three mice per group. * $P < 0.05$; Student's *t*-test.




Fig. 6. Expression of chemokine mRNAs in lungs of mice deficient in transforming growth factor (TGF)- β . (a) mRNA expression of various chemokines in the lungs of B6 mice treated with SB-431542 and control mice. Lungs were removed at 24 h after the final dose of SB-431542 or vehicle and total RNA was extracted. Chemokine expression (CCL2, CCL3, CCL4, CCL5, CCL11, CXCL1 and CXCL10) was detected by reverse transcription polymerase chain reaction (RT-PCR). (b) mRNA expression of various chemokines in the lungs of Smad3^{-/-} mice and control mice. Lungs were removed at 24 h after the third injection of interleukin (IL)-18/IL-2 and total RNA was extracted. Chemokine expression (CCL2, CCL3, CCL4, CCL5, CCL11, CXCL1 and CXCL10) was detected by RT-PCR. Representative results are shown of three experiments with similar findings.